A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

This study is testing how well a targeted immunotherapy medicine called naxitamab works when added to standard chemotherapy for children with a newly diagnosed, aggressive nerve cancer called neuroblastoma. Doctors hope that combining these treatments will help fight the cancer better and improve overall survival.

Children over one year of age with newly diagnosed, widespread neuroblastoma and certain specific genetic features may be eligible to join. However, children under one year old, those with certain low-risk features, or patients who have already received extensive prior cancer treatments cannot participate.

Participants will receive the new medicine, naxitamab, alongside their standard multi-agent chemotherapy across five treatment cycles. Doctors will carefully monitor their response to the treatment and overall health throughout the process.

The study is currently active and recruiting patients at multiple medical centers, including locations in Alabama, Arkansas, and California. You can talk to your care team to see if a nearby location is right for your family.